Influence of diltiazem and/or propranolol on rat blood glucose levels in normal and diabetic animals

Abstract

Diabetes mellitus and cardiovascular disorders are both common disorders, and it could be anticipated that they coexist in many patients. Diltiazem (DZ) is widely used alone or in combination with propranolol (PROP) for the treatment of hypertension and ischemic heart disease. These drugs could interfere with carbohydrate metabolism and impair glucose tolerance. The purpose of this study was to investigate the effect of oral administration of DZ, PROP (100 and 25 mg kg-1, respectively) and their combination on fasting serum glucose and insulin levels in normal and diabetic Wistar rats. Diabetes was induced by an intraperitoneal (i.p.) injection of streptozotocin (60 mg kg-1). In normal animals, serum glucose was significantly increased after DZ, PROP and DZ/PROP treatment compared to the initial values. In diabetic rats, serum glucose was significantly increased after PROP and DZ/PROP treatments, while it was slightly increased after diltiazem treatment compared to the initial values. In normal animals, plasma cAMP is significantly decreased in all treatment groups compared to the control value, while in the plasma of diabetic rats, cAMP was significantly decreased after PROP and DZ/PROP treatments when compared to the control value. Serum potassium of normal rats decreased after the diltiazem and DZ/PROP treatments, and they tend to increase slightly after PROP treatment. Serum potassium of diabetic rats was increased significantly after PROP and DZ/PROP treatments compared to the initial values. Body weight is decreased significantly in all treatment groups in normal rats while this significant decrease was observed only after DZ/PROP treatment in diabetic rats. This investigation suggests that diltiazem alone has no worsening effects on the glycemic control in diabetic rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Relation of morphometry and basal lactate production in primary culture of isolated adipocytes from normotensive and hypertensive rats.

“…The relationship between lactate production and adipocyte size, according to Digirolamo (3), is presented in a positive and significant way, with larger adipocytes being associated with a higher lactate levels in the blood. The Wistar-Kyoto (WKY) strain presents fasting glycemia similar to the SHR (spontaneously hypertensive rats) and Wistar rats (4,8), indicating that the blood glucose is not the determining factor for possible differences in lactate production between these strains. However, the highest weight found in WKY compared to Wistar and SHR (W: 496.8±6.01; WKY: 563.6±14.84, SHR: 274.1±7.466) (5,6) and greater area and diameter of their adipocytes (7) may be indicative of higher lactate production, matching with the Digirolamo studies.…”

Improved Method for the Synthesis of New 1,5-Benzothiazepine Derivatives as Analogues of Anticancer Drugs

“…A number of biological activities have been associated with it, such as antihypertensive [1,2], antiasthemic [2,3], analgesic [4], cardiovascular [5], platelate aggregation inhibitor and Ca antagonist [2]. Recently Ahmed et al [6,7] patented 1,5-benzothiazepine derivatives as potential anticancer drugs.…”

Synthesis of Fused Heterocyclic Compounds Derived from 2-Phenyl[1,5]benzothiazepin-4(5H)-One

“…1,5-Benzothiazepines were used for the synthesis of thiazolo [2,3-b]- (2) ; oxazino [2,3- (3) and different substituted derivatives (4)(5)(6) . It is well known that benzothiazepines have great importance in discovery of led compounds (7) and possess biological activities such as antihypertensive (8) , analgesic (9) , antidepressants (10) , antiulcer (11) , antagonist of several G-protein coupled receptors (12) and bradykinin agonist (13)(14)(15)(16) . The present work aims at the synthesis of a novel group of fused heterocyclic compounds containing 1,5-benzothiazepine nucleus which may possess biological activities.…”